Long-Term Treatment with Inhaled Steroids in Children with Asthma

2015 ◽  
pp. 282-284
Author(s):  
John Morrison Smith
Keyword(s):  
Term Treatment ◽  
Inhaled Steroids ◽  
Long Term Treatment ◽  
Children With Asthma

scholarly journals Usefulness of Nonvalved Spacers for Administration of Inhaled Steroids in Young Children with Recurrent Wheezing and Risk Factors for Asthma

2018 ◽  
Vol 2018 ◽  
pp. 1-5
Author(s):  
Carlos Kofman ◽  
Alejandro Teper
Keyword(s):  
Risk Factors ◽  
Fluticasone Propionate ◽  
Young Children ◽  
Respiratory Symptoms ◽  
Term Treatment ◽  
Recurrent Wheezing ◽  
Inhaled Steroids ◽  
Long Term Treatment ◽  
Metered Dose

Background. In vitro and scintigraphic studies have suggested that effectiveness of metered-dose inhalers (MDI) with nonvalved spacers (NVS) is similar to that of MDI with valved holding chambers (VHC). Nevertheless, there are no clinical studies that compare these techniques in long-term treatment with inhaled steroids in young children with recurrent wheezing and risk factors for asthma. Objective. To compare the efficacy of a long-term treatment with Fluticasone Propionate administered by an MDI through both type of spacers, with and without valves, in young children with recurrent wheezing and risk factors for asthma. Patients and Methods. Outpatient children (6 to 20 months old) with recurrent wheezing and risk factors for asthma were randomized to receive a 6-month treatment with metered-dose inhaler (MDI) of Fluticasone Propionate 125 mcg BID through an NVS or through a VHC. Parents recorded daily their child’s respiratory symptoms and rescue medication use. Results. 46 patients of 13.4 ± 5 months old were studied. During the study period, the NVS group (n=25) experienced 3.9 ± 2.4 obstructive exacerbations, and the VHC group (n=21) had 2.6 ± 1.6 (p=0.031). The NVS group had 17.4 ± 14% of days with respiratory symptoms, and the VHC group had 9.7 ± 7% (p=0.019). The NVS group spent 29.8 ± 22 days on albuterol while the VHC group spent 17.9 ± 11 days (p=0.022). Conclusion. Long-term treatment with inhaled steroids administered by MDI and NVS is less effective than such treatment by MDI and VHC in infants with recurrent wheezing and risk factors for asthma.

INFECTIONS AND VIRILIZING ADRENAL HYPERPLASIA

PEDIATRICS ◽  
1960 ◽  
Vol 25 (4) ◽  
pp. 563-564
Author(s):  
MARY L. VOORHESS ◽  
LYTT I. GARDNER
Keyword(s):  
Infectious Diseases ◽  
Replacement Therapy ◽  
Adrenal Glands ◽  
Term Treatment ◽  
Adrenal Hyperplasia ◽  
Long Term Treatment ◽  
Children With Asthma

PHYSICIANS who treat children with virilizing adrenal hyperplasia frequently question the proper course of therapy that should be followed when these patients are exposed to infectious diseases. Misconceptions have developed because of a tendency to confuse these patients, who need adrenocorticosteroids only for replacement therapy, with patients having other syndromes who are receiving suppression therapy. Children with virilizing adrenal hyperplasia are given long-term treatment with physiologic amounts of adrenocorticosteroids to replace those steroids which their adrenal glands are unable to produce. It is hoped that their abnormally large adrenal glands can thus be reduced to a normal size. This is replacement therapy. Children with asthma, leukemia, nephrosis, etc., may be given large doses of steroids in an empiric effort to induce remissions in these diseases.

Sign in / Sign up

Export Citation Format

Share Document